Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.
about
Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experienceLow-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunityIL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetesImmunoregulatory functions of mTOR inhibition.How tolerogenic dendritic cells induce regulatory T cellsAddition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice.The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes.Immunotherapy with Tolerogenic Dendritic Cells Alone or in Combination with Rapamycin Does Not Reverse Diabetes in NOD MiceLimitations of IL-2 and rapamycin in immunotherapy of type 1 diabetesDelayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+ CD4+ graft infiltrating cells.Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease.mTOR signaling in T cell immunity and autoimmunity.Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.Less is more: the detrimental consequences of immunosuppressive therapy in the treatment of type-1 diabetes.Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.Secretory mediators regulate Nod2-induced tolerance in human macrophages.Immunotherapy in type 1 diabetes: a shorter but more winding road?Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice.The problems and promises of research into human immunology and autoimmune disease
P2860
Q26850621-EE186808-BEA0-4623-8BBE-9276F300650BQ27008200-56AFE59F-2D75-4A02-90D3-FDD1ED03BC21Q27303126-BC3423C5-F10E-402D-87EA-73F7102927D4Q33761278-BF54CFA2-1CED-4808-94AF-8A44654A17D6Q34631825-7C52A031-D4B7-4177-922A-C2F858A1C034Q34796651-FA79D17B-EC1D-41CD-B07A-51764984D127Q35976619-1E4D089B-0F94-4FDC-AC86-804C86AA2435Q36716382-03F139E7-4049-442C-B132-EF9688984BC0Q37110531-F940383A-2536-4F2C-B83D-AD825C45F986Q37216199-37C9596A-BD7A-4AE0-A2D9-0EFA89BC5240Q37737987-864F6875-473C-40C1-9C23-549F28FFD9B2Q38229078-2CCB708D-23B3-4806-B418-0656B50A5F17Q38262670-DE122FA3-D7D9-490D-8372-50F9F905726FQ38385236-47892E81-3BC2-444B-9FAB-66117751ADB3Q38830417-6E47AC47-E315-45E6-9F2E-0D61DE7378E6Q38926045-FC956F5C-8F33-46B1-AE5B-6343A3219543Q42196429-FD0810B3-2DBF-4824-B35F-AF4145E5FDB2Q42287884-D45A66AD-F23C-4A6D-BA73-9C6B9C50CA72Q43199221-3E89B462-790E-4D40-9985-BC0254566E66Q57623514-4AE339CA-931D-4A70-A488-20B0256D3BD9
P2860
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.
@en
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.
@nl
type
label
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.
@en
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.
@nl
prefLabel
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.
@en
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.
@nl
P2093
P2860
P356
P1433
P1476
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.
@en
P2093
Andrea Valle
Angela Stabilini
Manuela Battaglia
Maria-Grazia Roncarolo
Mark Atkinson
Tatiana Jofra
P2860
P304
P356
10.2337/DB08-1432
P407
P577
2009-01-16T00:00:00Z